We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

25 hedge funds and large institutions have $3.93M invested in DiaMedica Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 3

0.32% more ownership

Funds ownership: 9.39% → 9.7% (+0.32%)

0% more capital invested

Capital invested by funds: $3.92M → $3.93M (+$6.45K)

7% less funds holding

Funds holding: 27 → 25 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
25
Holders Change
-2
Holders Change %
-7.41%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
9
Reduced
3
Closed
4
Calls
$13K
Puts
–
Net Calls
+$13K
Net Calls Change
+$21K

Top Buyers

Rank Fund Capital Flow
1
CLG
Cooperman Leon G
+$88.7K
2
Renaissance Technologies
Renaissance Technologies
New York
+$49K
3
CFP
Catalyst Financial Partners
Massachusetts
+$16.9K
4
Citadel Advisors
Citadel Advisors
Florida
+$4.79K
5
TRCT
Tower Research Capital (TRC)
New York
+$3.65K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$32.9K
2
Two Sigma Investments
Two Sigma Investments
New York
-$19.2K
3
Northern Trust
Northern Trust
Illinois
-$3.56K
4
UBS Group
UBS Group
Switzerland
-$2.73K
5
ASN
Advisory Services Network
Georgia
-$2.37K

DMAC Hedge Fund Activity: Q1 2023 in Review

25 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2023, worth a combined $3.93M — up 0.16% from $3.92M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of DMAC and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 9 added.

The largest buyer was Cooperman Leon G, adding an estimated $88.7K. The largest seller was Jane Street, exiting entirely with an estimated $32.9K sold.

  • 25 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2023, down from 27 in Q4 2022.
  • Funds reported $3.93M of DiaMedica Therapeutics stock for Q1 2023, up 0.16% quarter-over-quarter.
  • 2 funds opened new DiaMedica Therapeutics positions in Q1 2023 and 4 closed out, a net change of -2 holders.
  • The largest DiaMedica Therapeutics buyer in Q1 2023 was Cooperman Leon G, an estimated $88.7K added.
  • The largest DiaMedica Therapeutics seller in Q1 2023 was Jane Street, an estimated $32.9K sold.

Based on aggregated 13F filings for Q1 2023.